| Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, JS Lee, MJ Hochmair, ... New England Journal of Medicine 379 (21), 2027-2039, 2018 | 869 | 2018 |
| Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an … SK Kumar, JG Berdeja, R Niesvizky, S Lonial, JP Laubach, M Hamadani, ... The Lancet Oncology 15 (13), 1503-1512, 2014 | 322 | 2014 |
| Brigatinib versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer: second interim analysis of the phase III ALTA-1L trial DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, MJ Hochmair, KH Lee, ... Journal of Clinical Oncology 38 (31), 3592-3603, 2020 | 291 | 2020 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 243 | 2019 |
| Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma SK Kumar, WI Bensinger, TM Zimmerman, CB Reeder, JR Berenson, ... Blood, The Journal of the American Society of Hematology 124 (7), 1047-1055, 2014 | 242 | 2014 |
| Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients PG Richardson, R Baz, M Wang, AJ Jakubowiak, JP Laubach, RD Harvey, ... Blood, The Journal of the American Society of Hematology 124 (7), 1038-1046, 2014 | 232 | 2014 |
| A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis V Sanchorawala, G Palladini, V Kukreti, JA Zonder, AD Cohen, DC Seldin, ... Blood, The Journal of the American Society of Hematology 130 (5), 597-605, 2017 | 146 | 2017 |
| Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies CI Wong, TS Koh, R Soo, S Hartono, CH Thng, E McKeegan, WP Yong, ... Journal of clinical oncology 27 (28), 4718-4726, 2009 | 102 | 2009 |
| Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor JL Steinberg, N Gupta, RS Pradhan, SH Enschede, RA Humerickhouse US Patent App. 12/365,966, 2009 | 101 | 2009 |
| Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China … J Hou, J Jin, Y Xu, D Wu, X Ke, D Zhou, J Lu, X Du, X Chen, J Li, J Liu, ... Journal of hematology & oncology 10, 1-13, 2017 | 85 | 2017 |
| Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer EH Tan, GD Goss, R Salgia, B Besse, DR Gandara, NH Hanna, ... Journal of Thoracic Oncology 6 (8), 1418-1425, 2011 | 73 | 2011 |
| Switching from body surface area‐based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis N Gupta, Y Zhao, AM Hui, DL Esseltine, K Venkatakrishnan British Journal of Clinical Pharmacology 79 (5), 789-800, 2015 | 71 | 2015 |
| Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma S Kumar, P Moreau, P Hari, MV Mateos, H Ludwig, C Shustik, T Masszi, ... British journal of haematology 178 (4), 571-582, 2017 | 70 | 2017 |
| Clinical pharmacology of ixazomib: The first oral proteasome inhibitor N Gupta, MJ Hanley, C Xia, R Labotka, RD Harvey, K Venkatakrishnan Clinical Pharmacokinetics 58, 431-449, 2019 | 65 | 2019 |
| A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated … SK Kumar, JG Berdeja, R Niesvizky, S Lonial, M Hamadani, AK Stewart, ... Blood 120 (21), 332, 2012 | 58 | 2012 |
| A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis N Gupta, MJ Hanley, RD Harvey, A Badros, B Lipe, V Kukreti, J Berdeja, ... British Journal of Haematology 174 (5), 748-759, 2016 | 56 | 2016 |
| Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma SE Assouline, J Chang, BD Cheson, R Rifkin, S Hamburg, R Reyes, ... Blood cancer journal 4 (10), e251-e251, 2014 | 55 | 2014 |
| Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment N Gupta, MJ Hanley, K Venkatakrishnan, R Perez, RE Norris, ... British journal of clinical pharmacology 82 (3), 728-738, 2016 | 51 | 2016 |
| Investigational agent MLN9708, an oral proteasome inhibitor, in patients (Pts) with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a … PG Richardson, R Baz, L Wang, AJ Jakubowiak, D Berg, G Liu, N Gupta, ... Blood 118 (21), 301, 2011 | 51 | 2011 |
| Population pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor, including data from the phase III TOURMALINE-MM1 study to inform labelling N Gupta, PM Diderichsen, MJ Hanley, D Berg, H van de Velde, ... Clinical pharmacokinetics 56, 1355-1368, 2017 | 50 | 2017 |
